753 related articles for article (PubMed ID: 29032384)
1. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
2. Statin Use Is Associated With Decreased Osteoporosis and Fracture Risks in Stroke Patients.
Lin SM; Wang JH; Liang CC; Huang HK
J Clin Endocrinol Metab; 2018 Sep; 103(9):3439-3448. PubMed ID: 29982482
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
5. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
6. Association between diuretic use and the risk of vertebral fracture after stroke: a population-based retrospective cohort study.
Lin SM; Yang SH; Wang CY; Huang HK
BMC Musculoskelet Disord; 2019 Mar; 20(1):96. PubMed ID: 30832635
[TBL] [Abstract][Full Text] [Related]
7. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
8. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
9. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
Zhou B; Huang Y; Li H; Sun W; Liu J
Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
[TBL] [Abstract][Full Text] [Related]
10. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
11. Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures.
Yang SC; Chiu YC; Liu PH; Hsieh TJ; Kao YH; Tu YK
Osteoporos Int; 2019 May; 30(5):1043-1049. PubMed ID: 30706096
[TBL] [Abstract][Full Text] [Related]
12. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
Chen CH; Lin CL; Kao CH
Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
[TBL] [Abstract][Full Text] [Related]
14. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
15. Thiazide diuretics and the risk of hip fracture after stroke: a population-based propensity-matched cohort study using Taiwan's National Health Insurance Research Database.
Lin SM; Yang SH; Cheng HY; Liang CC; Huang HK
BMJ Open; 2017 Sep; 7(9):e016992. PubMed ID: 28963293
[TBL] [Abstract][Full Text] [Related]
16. The relationship between proton pump inhibitor adherence and fracture risk in the elderly.
Ding J; Heller DA; Ahern FM; Brown TV
Calcif Tissue Int; 2014 Jun; 94(6):597-607. PubMed ID: 24706060
[TBL] [Abstract][Full Text] [Related]
17. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools.
Sobel RE; Bate A; Marshall J; Haynes K; Selvam N; Nair V; Daniel G; Brown JS; Reynolds RF
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):332-339. PubMed ID: 29392851
[TBL] [Abstract][Full Text] [Related]
18. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.
Hussain S; Siddiqui AN; Habib A; Hussain MS; Najmi AK
Rheumatol Int; 2018 Nov; 38(11):1999-2014. PubMed ID: 30159775
[TBL] [Abstract][Full Text] [Related]
20. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
